Volume 131, Issue 1, Pages 59-68 (July 2006) Kinetics and Risk of De Novo Hepatitis B Infection in HBsAg–Negative Patients Undergoing Cytotoxic Chemotherapy  Chee–Kin Hui, Winnie W.W. Cheung, Hai–Ying Zhang, Wing–Yan Au, Yui–Hung Yueng, Anskar Y.H. Leung, Nancy Leung, John M. Luk, Albert K.W. Lie, Yok–Lam Kwong, Raymond Liang, George K.K. Lau  Gastroenterology  Volume 131, Issue 1, Pages 59-68 (July 2006) DOI: 10.1053/j.gastro.2006.04.015 Copyright © 2006 American Gastroenterological Association Institute Terms and Conditions

Figure 1 Serial serum alanine aminotransaminase, HBV DNA, and HBV serology of 2 patients (patient 6 and patient 7) who developed de novo HBV-related hepatitis. Arrow, Time lamivudine was commenced. (B) R+CHOP, rituximab, cyclophosphamide, adriamycin, vincristine, prednisolone; (A) R+FND, rituximab, fludarabine, mitoxantrone, dexamethasone; LOD, limit of detection. Gastroenterology 2006 131, 59-68DOI: (10.1053/j.gastro.2006.04.015) Copyright © 2006 American Gastroenterological Association Institute Terms and Conditions

Figure 2 Cumulative probability of developing de novo HBV-related hepatitis after chemotherapy in relation to (A) rituximab plus steroid-containing regimen and (B) rituximab-containing regimen. Gastroenterology 2006 131, 59-68DOI: (10.1053/j.gastro.2006.04.015) Copyright © 2006 American Gastroenterological Association Institute Terms and Conditions

Figure 3 Cumulative probability of fulminant hepatic failure in relation to (A) de novo hepatitis B virus related hepatitis and (B) hepatitis B core antibody. Gastroenterology 2006 131, 59-68DOI: (10.1053/j.gastro.2006.04.015) Copyright © 2006 American Gastroenterological Association Institute Terms and Conditions